Molecular and cellular aspects of hepatitis C virus reinfection after liver transplantation: how the early phase impacts on outcomes.
Hepatitis C virus (HCV)-related liver disease postliver transplantation is associated with an accelerated course in comparison with that observed in the nonimmunosuppressed individual. Outcomes in transplantation for this indication have, therefore, been a major area of clinical interest in the field of liver transplantation. The factors underlying the rapid progression of HCV-related liver disease posttransplantation are complex and multifactorial. Nevertheless, recent data indicate a range of parameters assessable early posttransplantation that may be useful in the prediction of outcome of transplantation for this condition. This overview, therefore, concentrates on the early events occurring postliver transplantation in the HCV-infected patient, and the implications of these recent observations for the pathogenesis of the various forms of HCV-related allograft injury.
McCaughan
Geoffrey W
GW
AW Morrow Gastroenterology and Liver Centre, Centenary Institute, Royal Prince Alfred Hospital and Sydney University, Sydney, Australia. g.mccaughan@centenary.usyd.edu.au
Shackel
Nicholas A
NA
Bertolino
Patrick
P
Bowen
David G
DG
D006084:Graft Rejection; D016174:Hepacivirus / Q000502:physiology; D006526:Hepatitis C / Q000453:epidemiology* / Q000601:surgery*; D019698:Hepatitis C, Chronic / Q000453:epidemiology / Q000601:surgery; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000276:immunology / Q000401:mortality / Q000706:statistics & numerical data*; D011183:Postoperative Complications / Q000453:epidemiology / Q000821:virology; D012008:Recurrence; D015427:Reperfusion Injury / Q000453:epidemiology; D017741:Survivors; D016896:Treatment Outcome; D014766:Viremia / Q000453:epidemiology; D014779:Virus Replication
D007166:Immunosuppressive Agents